Abstract:Abstract This study is aimed to identify serum biomarkers that predict treatment response and survival by screening proximity ligation assay (PLA) and verified enzyme-linked immunosorbent assay (ELISA) for patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant concurrent chemoradiotherapy (CCRT) followed by esophagectomy. One hundred and three patients with ESCC receiving CCRT consisting of taxane-/5-fluorouracil-based chemotherapy and 40Gy radiotherapy followed by surgery were prospectively enrolled. Serum samples were collected before and within 1 month after completion of CCRT. With the use of PLA, 15 biomarkers were simultaneously analyzed in the initial 79 patients. The biomarkers significantly associated with pathological response (PathR)/survival were verified by ELISA in an expanded group of 103 patients. Associations between serum levels of biomarkers and clinical factors correlating with PathR, disease-free survival (DFS), and overall survival (OS) were evaluated by ANOVA and log-rank tests. Following CCRT, 38 patients had pathologically complete response (37%), 44 microscopic (43%), and 21 macroscopic residual disease (20%). With a median follow-up of 66 months, the median DFS and OS were 23.7 months and 43.5 months, respectively. Among the 15 biomarkers screened by PLA, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1) were significantly associated with PathR and/or DFS. These biomarkers were further analyzed by ELISA to confirm initial biomarker findings by PLA. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR (p=0.042 and 0.019, respectively). Patients with high pre-CCRT VEGF-A/TGF-β1 levels (≥median) had significantly worse median DFS (9.3 months vs. 34.6 months, p=0.007) and worse median OS (26.7 months vs. 51.5 months, p=0.05). On multivariate analysis, PathR (p=0.001) and pre-CCRT high levels (≥median) of both VEGF-A and TGF-β1 (p=0.005) were independent factors for DFS. PathR (p=0.002) was the only significant factor for OS, while pre-CCRT high levels of both VEGF-A and TGF-β1 were borderline significant (p=0.065). In conclusion, serum VEGF-A may be used to predict post-CCRT pathological response. High serum levels of VEGF-A and TGF-β1 before CCRT associate with significantly worse DFS and a trend toward worse OS. Citation Format: Jason Chia-Hsien Cheng, Yun Chiang, Feng-Ming Hsu, Chiao-Ling Tsai, Chih-Hung Hsu, Jang-Ming Lee. Serum biomarkers of VEGF-A and TGF-β1 predict pathological response and survival of esophageal cancer patients treated with neoadjuvant chemoradiotherapy and esophagectomy. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A002.

Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma

The Negative Expression of Annexin A1 in Esophageal Squamous Cell Carcinoma is Associated with Poor Outcome

Association of Nuclear Annexin A1 with Prognosis of Patients with Esophageal Squamous Cell Carcinoma.

Annexin-1 Downregulation is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma

Abstract A002: Serum Biomarkers of VEGF-A and TGF-β1 Predict Pathological Response and Survival of Esophageal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy and Esophagectomy

Effect of Annexin A1 gene on the proliferation and invasion of esophageal squamous cell carcinoma cells and its regulatory mechanisms

Decreased Annexin A1 Expression Enhances Sensitivity to Docetaxel, Cisplatin and 5-Fluorouracil Combination Induction Chemotherapy in Oral Squamous Cell Carcinoma

Low Annexin A1 Expression Predicts Benefit from Induction Chemotherapy in Oral Cancer Patients with Moderate or Poor Pathologic Differentiation Grade

Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma

Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

ANO1 Protein As a Potential Biomarker for Esophageal Cancer Prognosis and Precancerous Lesion Development Prediction.

Mir-196A Regulates the Proliferation, Invasion and Migration of Esophageal Squamous Carcinoma Cells by Targeting ANXA1.

Annexin A4 and cancer

Expression of Annexin A5 is Associated with Higher Tumor Stage and Poor Prognosis in Colorectal Adenocarcinomas.

Tissue Microarray Analysis Reveals Strong Clinical Evidence for a Close Association Between Loss of Annexin A1 Expression and Nodal Metastasis in Gastric Cancer

Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.

Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

Increased Expression of High-Mobility Group A2: A Novel Independent Indicator of Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.

Differential Expression of ANXA1 in Benign Human Gastrointestinal Tissues and Cancers

[Dysregulation of Annexin II Expression in Esophageal Squamous Cell Cancer and Adjacent Tissues from a High-Incidence Area for Esophageal Cancer in Henan Province].